Gerald Chan
Directeur/Membre du Conseil chez Cognito Therapeutics, Inc.
Postes actifs de Gerald Chan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Cognito Therapeutics, Inc.
 Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Gerald Chan
Anciens postes connus de Gerald Chan
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Stavvy, Inc.
 Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Directeur/Membre du Conseil | - | - |
Statistiques
Internationale
| Etats-Unis | 3 |
Opérationnelle
| Director/Board Member | 2 |
Sectorielle
| Technology Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Stavvy, Inc.
Stavvy, Inc. Packaged SoftwareTechnology Services Stavvy, Inc. provides information technology services. The company is headquartered in Newton, MA. | Technology Services |
Cognito Therapeutics, Inc.
Cognito Therapeutics, Inc. BiotechnologyHealth Technology Cognito Therapeutics, Inc. is a clinical-stage neurotechnology company based in Cambridge, MA. Cognito Therapeutics is developing disease-modifying therapeutic approaches to treat neurodegenerative disorders using its non-invasive neuromodulation platform. The company's lead therapy is currently in a pivotal study (HOPE) in Alzheimer's disease and has been awarded FDA breakthrough device designation. Cognito Therapeutics is advancing the field of neuromodulation to create novel therapeutics that improve the lives of patients living with neurodegenerative diseases. The company was founded by Li-Huei Tsai and Ed Boyden, and Brent A. Vaughan has been the CEO of the company since 2020. | Health Technology |
- Bourse
- Insiders
- Gerald Chan
- Expérience
